Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.3.1.21 (CPT)
 4,580 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The movement of alpha-linolenic acid (C18:3, n-3) through the mitochondrial outer membrane to oxidation sites was studied in rat liver and compared with the movement of linoleic acid (C18:2, n-6) and oleic acid (C18:1, n-9). All differ in the degree of unsaturation, but have the same chain length and the same position of the first double bond when counted from the carboxyl end. The following results were obtained. (1) The overall beta-oxidation in total mitochondria was in the order C18:3, n-3 greater than C18:2, n-6 greater than C18:1, n-9, independent of the amount of albumin in the medium. (2) The rate of formation of acylcarnitine from acyl-CoA was higher with oleoyl-CoA than with linoleoyl-CoA, and remained very low with alpha-linolenoyl-CoA for all concentrations studied. (3) When the formation of acylcarnitines originated from fatty acids (as potassium salts) in a medium containing CoA and ATP, the conversion of alpha-linolenate was greater than that of linoleate, which in turn was greater than that of oleate. (4) Use of a more purified mitochondrial fraction, practically devoid of peroxisomes, did not modify the results obtained with alpha-linolenate. (5) alpha-Linolenoyl-CoA did not inhibit oxidation of labelled alpha-linolenate, whereas the other acyl-CoAs did. (6) Transfer to carnitine of all three fatty acids (as potassium salts) by carnitine palmitoyltransferase-I (CPT-I) was similarly inhibited by increasing concentrations of malonyl-CoA. (7) On using a fraction containing mitochondrial outer membranes, the formation of acylcarnitines from potassium salts of fatty acids was qualitatively and quantitatively similar to that found with whole mitochondria. (8) Our observations show that alpha-linolenoyl-CoA synthesized other than in the mitochondria cannot be used to any great extent by the mitochondria due to its configuration. However when added as the unactivated form, alpha-linolenate appears to be very quickly oxidized, but should first be activated by acyl-CoA synthetase in the mitochondrion itself. Then it is rapidly channelled to CPT-I. These enzymic sites are probably close together in the mitochondrial outer membrane. The different behaviour of the alpha-linolenic group compared with the other acyl groups in the studied pathway can be explained by a different spatial arrangement due to the number and position of the double bonds.
 ...
PMID:Pathway of alpha-linolenic acid through the mitochondrial outer membrane in the rat liver and influence on the rate of oxidation. Comparison with linoleic and oleic acids. 259 32

Mitochondrial acylcarnitine synthesis is an obligatory step in the transport of cytosolic long-chain FA into the mitochondria. It is an important control point in the partitioning of cytosolic fatty acids to synthetic pathways or to mitochondrial beta-oxidation. Mitochondrial carnitine palmitoyltransferase I (CPT I; EC 2.3.1.21) is the enzyme that catalyzes the transformation of long-chain fatty acylCoA esters to acylcarnitine. Additionally, the isoform of acylCoA synthetase (EC 6.2.1.3) found in mitochondria, which is in close proximity to CPT I on the outer membrane, may act in concert with CPT I to form acylcarnitines from cytosolic nonesterified FA (NEFA). The mitochondrial acylcarnitine synthesis pathway is exposed to multiple fatty acid substrates present simultaneously in the cell milieu, with each fatty acid present at varying pool sizes. The selectivity of this pathway for any particular fatty acid substrate under conditions of multisubstrate availability has not yet been tested experimentally. Our objective was to develop mathematical equations that make use of kinetic constants derived from single-substrate experiments to predict the selectivity of the acylcarnitine synthesis pathway under conditions in which two or more substrates are present simultaneously. In addition, the derived equations must be verifiable by experiment. Our approach was to begin with a Michaelis-Menten model that describes the initial rates of an enzyme system acting on multiple and mutually competitive substrates. From this, we derived equations expressing ratios of reaction rates and fractional turnover rates for pairs of substrates. The derived equations do not require assumptions concerning the degree of enzyme saturation. Using rat mitochondrial preparations and the NEFA substrate pairs, linolenic-oleic acids and palmitic-linoleic acids, we showed that the shape of the experimentally derived data on acylcarnitine synthesis fits the predictions of the derived model equations. We further validated the derived equations by showing that their predictions calculated from previously published kinetic constants were consistent with data from actual experiments. Thus, we are able to conclude that with respect to acylcarnitine synthesis, the fractional turnover rate of the linolenic acid pool would always be 2.9-fold faster than that of the oleate pool regardless of the pool size of either fatty acid. Similarly, the fractional turnover rate of the palmitate pool would always be 1.8-fold faster than that of the linoleate pool regardless of pool size. We extended our kinetic model to more than two mutually competitive substrates. Using previously published rate constants for eight physiologically relevant fatty acids, the derived model predicts that regardless of pool size of any of the fatty acids, the linolenate pool, whether as NEFA or as a CoA ester, would always have the highest fractional turnover rate with respect to acylcarnitine synthesis. Conversely, the stearate pool whether as NEFA or as CoA ester will have the lowest fractional turnover rate relative to all the other fatty acids.
 ...
PMID:Kinetic analysis of the selectivity of acylcarnitine synthesis in rat mitochondria. 1284 98

Patients with mitochondrial long-chain fat oxidation deficiencies are usually treated with diets containing reduced fat and increased carbohydrate, at times via gastrostomy feeding. To ensure adequate intake of essential fatty acids, supplements are provided to their diets using commercially available oils. These oils contain large quantities of non-essential fats that are preferentially oxidized and produce disease-specific metabolites (acyl-CoA intermediates) due to the genetic defect. This study describes the concentrations of these intermediates as reflected by acylcarnitines as well as the % contribution from each of four fatty acids: palmitate, oleate, linoleate, and alpha-linolenate when incubated with fibroblasts from patients with VLCAD, LCHAD, and trifunctional protein (TFP) deficiencies. Palmitate and oleate produce the majority of disease-specific acylcarnitines with these defective cell lines (79-94%) whereas linoleate and linolenate produced less (6-21%). On average, the amount of acylcarnitines decreased with increasing unsaturation (C18:1>C18:2>C18:3:34%>11%>3%, respectively. This relationship may reflect the "gatekeeper" role of carnitine palmitoyltransferase I (CPT I). A diet comparison between Canola and a combination of Flax/Walnut oils revealed that the latter, containing the least amount of non-essential fats, reduced blood acylcarnitine levels by 33-36%. The etiology of the severe peripheral neuropathy of TFP deficiency may result from the unique metabolite, 3-keto-acyl-CoA, after conversion to a methylketone via spontaneous decarboxylation. Essential fatty acid supplementation with oils should consider these findings to decrease production of disease-specific acyl-CoA intermediates.
 ...
PMID:Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. 1782 94